Andrew Ko, MD, FASCO, University of California, San Francisco, CA, discusses developments in the treatment of pancreatic cancer, including findings from the Phase III NAPOLI-3 trial (NCT04083235), which compared liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX) to nab-paclitaxel with gemcitabine in previously untreated patients with metastatic pancreatic ductal adenocarcinoma. Dr Ko also talks on the future role of targeted therapies such as sotorasib and adagrasib in KRAS G12C-mutant pancreatic cancer, and immunotherapy. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

John L. Marshall, MD; Eileen M. O’Reilly, MD; George P. Kim, MD; Kabir Mody, MD; and Tanios S. Bekaii-Saab, MD, describe their personal approaches to treating metastatic pancreatic cancer in the frontline setting, including patient selection, toxicity management, and supportive care.

Dr. Robert Herman Vonderheide, MD, DPhil, is an internationally renowned cancer immunotherapy and translational research expert. Through a focus on novel immunotherapies for pancreatic cancer, melanoma, and breast cancers, Dr. Vonderheide has mapped new models for speeding translational - or "bench to bedside" research. He'll be with us to discuss the latest advances in immunotherapy to treat pancreatic cancer, one of the hardest cancers to treat.